Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma: A Southwest Oncology Group study

Roy L. Martino, Thomas R. Fleming, Louise M. Morrell, Bach Ardalan, Stephen P. Richman, John S. Macdonald

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

N-(phosphonacetyl)-disodium L-aspartic acid (PALA) demonstrates a synergistic antitumor effect when combined with 5-Fluorouracil (5-FU)in in vitro studies. In a Phase II trial, 23 eligible patients with unresectable or metastatic adenocarcinoma of the stomach-were treated with weekly i.v. bolus PALA (250 mg/M2) followed 24 hours later by a 24-hour infusion of 5-FU (2600 mg/M2) for an initial period of 8 weeks. No objective responses were noted. PALA and 5-FU is inactive against gastric adenocarcinoma at the doses and schedule used in this trial.

Original languageEnglish (US)
Pages (from-to)419-421
Number of pages3
JournalInvestigational New Drugs
Volume14
Issue number4
StatePublished - Dec 1 1996
Externally publishedYes

Keywords

  • 5-Fluorouracil
  • Advanced gastric cancer
  • PALA
  • Phase II study

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-Fluorouracil in advanced gastric adenocarcinoma: A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this